

## Robert J. Brent Curriculum Vitae, Fall 2023.

Fordham University  
Department of Economics

Phone: Home: (718) 817 – 4058.  
Cell: (718) 644 – 9175.

441 East Fordham Road  
Bronx, NY 10458

e-mail: [brent@fordham.edu](mailto:brent@fordham.edu)  
Website: [www.fordham.edu/economics/brent](http://www.fordham.edu/economics/brent)

**Personal Details:** US Citizen.

**Current Position:** 2023 – : Professor Emeritus, Department of Economics, Fordham University, New York.  
1995 – 2022: Professor, Department of Economics, Fordham University, New York.  
1980 – 1995: Associate Professor, Department of Economics, Fordham University.

### Previous Position:

1998 - 1999: (On leave) Senior Research Fellow and Coordinator for Strategic Planning and Governance Program, Asian Development Bank Institute, Kasumigaseki Building 8F, 3-2-5 Kasumigaseki, Chiyoda-ku, Tokyo, 100-6008, Japan

### Other Positions:

1977 - 1980: Assistant Professor, Department of Economics, University of Essex, England.  
1974 - 1977: Assistant Professor, Department of Economics, University of Nairobi, Kenya.  
1971 - 1974: Assistant Professor, Department of Business and Economics, Nottingham-Trent University, England.

### Other Appointments:

- Spring 2007: Visiting Professor, Health Economics Unit, School of Public Health, University of Cape Town, South Africa.
- Spring 2003: Visiting Professor, Department of Economics, University of Dar es Salaam, Tanzania.
- Spring 2002: Visiting Professor, Georgetown University, School of Nursing and International Health, Washington D.C.
- Jan 1995 – July 1997: Research Scientist / Economist (Part Time) Nathan Kline Institute for Psychiatric Research, Orangeburg, NY 10962.
- Spring 1993: Visiting Associate Professor, Department of Economics, Columbia University, New York.
- Fall 1992: Adjunct, Program in Economic Policy Management, Columbia University, New York. [Masters Program Sponsored by the World Bank.]
- Summer 1992: Fellow and Visiting Professor of Economics, National Institute of Public Finance and Policy, New Delhi, India. [Health Care Finance Project.]
- Spring 1987: Visiting Associate Professor, Department of Economics, Syracuse University, New York.

**Fields of Interest:** Health (I); Development (O); Public Economics (H).

### Education:

<i>Degree</i>	<i>Field</i>	<i>Institution</i>	<i>Year</i>
Ph.D.	Economics	University of Manchester (UK)	1976.
M.A. Econ.	Economics	University of Manchester (UK)	1969.
B.A. Econ.	Economics	University of Kent at Canterbury (UK)	1968.

## **Teaching:**

**MA and Ph.D:** Health Care Evaluations, Health Sector Economics, Public Sector Economics, Applied Econometrics, Public Finance, Cost-Benefit Analysis, Project Appraisal for Developing Countries, Taxation for Developing Countries, Managerial Economics.

**Undergraduate:** Health Sector Economics, Health Care Evaluations, Statistics I and II, Microeconomics and Macroeconomics, Public Finance, Principles of Cost-Benefit Analysis.

## **Professional Activities:**

**Keynote Speaker at the 11<sup>th</sup> International Conference on Dementia and Dementia Care**, February 19-20 2020 in Paris, France. Presentation on “Cost-Benefit Analysis of Dementia Interventions.”

**Keynote Speaker at the 12<sup>th</sup> World Congress on Dementia and Alzheimer Rehabilitation**, April 11-12 2019 in Stockholm, Sweden. Presentation on “Cost-Benefit Analysis of Dementia Interventions.”

**Chair and Member of the European Union Scientific Committee** related to the “Study on Identifying and Aggregating Elasticities for spill-over Effects due to Linkages and Externalities in the Main Sectors of Investment Co-financed by the EU Cohesion Policy.” Jan 2010 to July 2011. Study completed and accepted July 2011.

**Copenhagen Consensus Participant:** Wrote the Perspectives Paper on CBAs of Treatment as part of the 2011 Project on HIV/AIDS in Sub-Saharan Africa called **ReThink HIV** funded by the Rush Foundation

**Consultant for the Inter-American Development Bank:** Commissioned to write the Guidelines for Carrying out CBAs of Social Projects at the Bank. Report completed and accepted July 2011.

**Fulbright Scholar Award**, January – July 2003. Project: CBA of AIDS Prevention Programs in Tanzania.

**Professional Affiliations:** American Economic Association (AEA). International Health Economics Association (iHEA, on the Scientific Committee 2010/2011, 2012/201, 2014/2015, 2016/2017, 2018/2019, 2020/2021) and American Society of Health Economists (ASHE, on the Scientific Committee 2006/2007). Member of Sigma Xi. AIDS Community Research Initiative of America, NYC.

**NGOs:** Treasurer and Member of the NGO Executive Committee on Ageing (2013 – 2015). Treasurer and Member of the Board of the International Network for the Prevention of Elderly Abuse (2009 – 2013). UN Representative for INPEA, 2009-2024. On the Executive Committee and Member of the UN NGO Committee on HIV/AIDS (2002–2013).

**Grants And Fellowships:** Faculty Research Grants from the University of Nairobi, 1976, and Fordham University, 1984, 2007, 2012. Faculty Fellowships from Fordham University, 1987, 1993, 2003, 2008, 2014 and 2019. Inter-American Development Fund, SPD section, Sponsored Research Grant, 2010-2011.

## **Conference Papers and Recent Seminars Presented:**

**Conferences: National ASSA Meetings:** Chicago 2012, Philadelphia 2005, San Diego 2004, Boston, 2000 and 1994; **World Health Congress (iHEA):** Cape Town, 2023, Online, 2021, Boston 2017, Milan 2015, Sydney 2013, Toronto 2011, Beijing 2009, Copenhagen 2007; Barcelona 2005, York 2001. **ASHE:** Duke 2008, Madison 2006. **Society for BCA**, Washington D.C.: 2021–2024, 2017–2019, 2012.

**Seminars:** Makerere, Kampala, Nkumba, Muteesa and Busoga Universities in Uganda; Kigali University and Rwanda Biomedical Medical Center in Rwanda; University of Nairobi in Kenya; University of Cape Town, University of Pretoria, University of Witwatersrand in South Africa; Georgetown University, School of Nursing and International Health; Yale College Seminar; Harvard University, School of International Health and Population; National Institute of Public Finance and Policy, New Delhi; Public Economics Division, World Bank, Washington D.C.; Asian Development Bank Institute, Tokyo. Inter-American Development Bank, Washington D.C.

**Referee for:**

The Open Health Services and Policy Journal (also Editorial Board Member), Journal of Public Economics, International Economic Review, Public Finance Review, Applied Economics, Journal of Development Economics, Journal of Economics and Business, Scottish Journal of Political Economy, Canadian Journal of Economics, Oxford Economic Papers, Social Science and Medicine, and the American Economist.

**Publications:**

*Articles in Economics Journals:* Single authored.

1. "A Cost-Benefit Analysis of Beta-Blockers, Including the Benefits of Reducing the Symptoms of Dementia." *Applied Economics* (2024), DOI: 10.1080/00036846.2024.2311078
2. "FDA-approved Medications for Dementia are Unlike Non-pharmacological Interventions as they are Counterproductive." *Applied Economics* (2023), DOI: 10.1080/00036846.2023.2178625
3. "Use of Distributional Weights in Cost-Benefit Analysis Revisited." *Applied Economics* (2023). DOI: 10.1080/00036846.2023.2206627
4. "Cost-Benefit Analysis versus Cost-Effectiveness Analysis from a Societal Perspective in HealthCare." *International Journal of Environmental Research and Public Health* (2023), Vol. 20, No.5, 4647. DOI: 10.390/ijerph20054644.
5. "Use Cost-Benefit Analysis and not Political Parties to Determine Government Expenditure Decisions." *Review of Economics and Finance* (2022), Vol. 20, 124-127.
6. "The Benefits of Not Living in Nursing Homes." *Applied Economics* (2022), Vol. 54, No. 32, 3740-3750.
7. "Life Expectancy in Nursing Homes." *Applied Economics* (2022), Vol. 54, No. 16, 1877-1888.
8. "Detecting the Incidence and Benefits Foregone of Elder Abuse Neglect: The Case of Hearing Aids in Nursing Homes." *Review of Economics and Finance* (2021), Vol 19, 169-175.
9. "A CBA of Corrective Lenses, Including the Benefits for Reducing the Symptoms of Dementia." *Applied Economics* (2020), Vol. 52, No. 48, 5218-5229.
10. "A CBA of Hearing Aids, Including the Benefits of Reducing the Symptoms of Dementia." *Applied Economics* (2019), Vol. 51, No. 28, 3091-3103.
11. "Estimating the Monetary Benefits of Medicare Eligibility for Reducing the Symptoms of Dementia." *Applied Economics* (2018), Vol. 50, No. 58, 6327-6340.

12. "The Value of a Year's General Education for Reducing the Symptoms of Dementia." *Applied Economics* (2018), Vol. 50, No. 25, 2812–282.
13. "Using the Travel Cost method to Value Visits and Stigma in Connection with ARV Adherence in Uganda." *Applied Economics* (2017), Vol 49, No. 5, 477-497.
14. "The Value of Reducing HIV Stigma." *Social Science & Medicine* (2016), Vol.151, 233-240.
15. "Valuing the Prevention of Elder Abuse." *Applied Economics* (2015), Vol. 47, No. 58, 6362-6373.
16. "Female Education, HIV/AIDS and the Education Vaccine in Sub-Saharan Africa: The Condoms Piece of the Puzzle." *Journal of African Development* (2014), Vol. 16, No.2, 41-71.
17. "A Cost-Benefit Framework for Evaluating Conditional Cash-transfer Programs." *Journal of Benefit Cost-Analysis* (2013), Vol. 4, No. 4, 159 -180.
18. "The Effects of HIV Medications on the Quality of Life of Older Adults in New York City." *Health Economics* (2012), Vol. 21, No. 8, 967 -976.
19. "An Implicit Price of a DALY for Use in a Cost-Benefit Analysis of ARVs." *Applied Economics* (2011), Vol.43, 1413-1421.
20. "A Social Cost-Benefit Criterion for Evaluating Voluntary Counseling and Testing with an Application to Tanzania." *Health Economics* (2010), Vol. 19, 154-172.
21. "Why Have Both Subsidized and Free Condoms to Prevent HIV/AIDS in Sub-Saharan Africa?" *Journal of African Development* (2010), Vol.12, No.2, 61-71.
22. "A Cost-Benefit Analysis of Female Primary Education as a Means of Reducing HIV-AIDS in Tanzania." *Applied Economics* (2009), Vol.41, No. 14, 1731-1743.
23. "A Cost-Benefit Analysis of a Condom Social Marketing Program in Tanzania." *Applied Economics* (2009), Vol. 41, No. 4, 497-509.
24. "The Role of User Fees in the Cost-Benefit Analysis of Privatization with an Application to Hospital Psychiatric Services in the US." *Applied Economics* (2008), Vol. 40, No.15, 1981-1989.
25. "Does Female Education Prevent the Spread of HIV-AIDS in Sub-Saharan Africa?" *Applied Economics* (2006), Vol. 38. No. 5, 491-503.
26. "The Role of Public and Private Transfers in the Cost-Benefit Analysis of Mental Health Programs." *Health Economics* (2004), Vol.13, No.11, 1125-1136.
27. "The Tax Implications of Cost Shifting in Cost-Benefit Analysis in Mental Health", *Applied Economics* (2003), Vol. 35, 943-950.
28. "A Simple Method for Converting a Cost-Effectiveness Analysis into a Cost-Benefit Analysis with an Application to State Mental Health Expenditures." *Public Finance Review* (2002), Vol. 30, No.2, 144-160. [Formerly *Public Finance Quarterly*]
29. "Estimating the Effectiveness and Benefits of Alcohol Treatment Programs for Use in Economic Evaluations." *Applied Economics* (1998), Vol. 30, 217-226.

30. "Cost-Benefit Analysis, User Prices and State Expenditures in India." *Public Finance* (1995), Vol. 50, No.3, 327-341.
31. "The Shadow Prices for a Physician's Services." *Applied Economics* (1994), Vol. 26, No. 7, 669-676.
32. "Country Estimates of Social Discount Rates Based on Changes in Life Expectancies." *Kyklos* (1993), Vol. 46, Fasc.3, 399-409.
33. "The Consumption Rate of Interest and the Numbers Effect." *Public Finance* (1992), Vol. 47, No.3, 367-377.
34. "On the Estimation Technique to Reveal Government Distributional Weights." *Applied Economics* (1991), Vol. 23, 985-992.
35. "A New Approach to Valuing a Life." *Journal of Public Economics* (1991), Vol. 44, 165-171.
36. "The Cost-Benefit Analysis of Government Loans." *Public Finance Quarterly* (1991), Vol. 19, 43-66.
37. "The Numbers Effect and the Shadow Wage in Project Appraisal." *Public Finance* (1991), Vol.46, 118-127.
38. "The Farmers Home Administration's Social Discount Rate." *Applied Economics* (1989), Vol. 21, 1247-1256.
39. "An Axiomatic Basis for the Three Objective Social Welfare Function Within a Poverty Context." *Economics Letters* (1986), Vol. 20, 89-94.
40. "Lagged Reactions in Short-run Estimates of Tax Shifting of Company Income and Sales Taxes in Kenya." *Journal of Development Economics* (1986), Vol. 20, 15-32.
41. "A Three Objective Social Welfare Function for Cost-Benefit Analysis." *Applied Economics* (1984), Vol. 16, 369-378.
42. "Use of Distributional Weights in Cost-Benefit Analysis: A Survey of Schools." *Public Finance Quarterly* (1984), Vol. 12, 213-230.
43. "Distinguishing Between Money Income and Utility Income in Cost-Benefit Analysis." *Public Finance Quarterly* (1980), Vol. 8, No.2, 131-152.
41. "Imputing Weights Behind Past Railway Closure Decisions Within a Cost-Benefit Framework." *Applied Economics* (1979), Vol. 9, No.2, 157-170.
42. "A Cross-Section Framework for Estimating Jointly the Extent of Shifting of Sales and Company Income Taxes, with an Application to Kenya." *Public Finance* (1979), Vol. 34, No.1, 151-168.

**Articles in Other Journals:** Single and jointly authored.

43. "Misconceptions Regarding Dementia: What it is, What Can be Done and What Should be Done." *International Journal of Psychology and Behavior Analysis* (2021), 7: 181.  
<https://doi.org/10.15344/455/2455-3867/2021/181>. Published December 16, 2021.

44. "Behavioral versus Biological Definitions of Dementia Symptoms: Recognizing that Worthwhile Interventions already Exist." *OBM Geriatrics* (2019), Vol. 3, No. 4, 2-14, doi:10.21926.
45. "Back to the Future: A Retrospective Cost Benefit Analysis of an Education Dropout Program as an Intervention to Prevent Reincarceration." *Journal of Offender Rehabilitation* (2019), Vol.57, number 7, 481-505. [With Dr. Tina Maschi].
46. "An Estimate of the Benefits of not Having HIV/AIDS in a Prison Setting." *Clinical Research in HIV/AIDS* (2015), Vol.2, No.2, 1022-1099. [With Dr. Tina Maschi].
47. "Using a Happiness Index to Measure the Benefits for a Cost-benefit Analysis of Antiretrovirals for Older Adults with HIV in New York City." *Clinical Research in HIV/AIDS* (2014), Vol.1, No.2, 1009-1019. [With Dr. Mark Brennan and Dr. Stephen E. Karpiak.]
48. "The Economic Value of Reducing the Stigma of HIV/AIDS." *Expert Review of Pharmacoeconomics & Outcomes Research* (2013), Vol.13, No. 5, 561-563.
49. "Economic Evaluations of HIV Prevention in Rich Countries and the Need to Focus on the Aging of the HIV-positive Population." *Current Opinion in HIV and AIDS* (2010), Vol. 5, 255-260. [With Dr. Mark Brennan and Dr. Stephen E. Karpiak.]
50. "Profits, Poverty, and Health Care: An Examination of the Ethical Base of Economics." *Fordham Urban Law Journal* (1997), Vol. 24, No.4, 667-681.
51. "Physician Rewards for Different Kinds of Service: The RBRVS and the CPR Systems." *Plastic and Reconstructive Surgery* (1997), Vol. 100, July, 51-57. [With Dr. Mahendra Patel]
52. "Counting and Double-Counting in Project Appraisal." *Project Appraisal* (1994), Vol.9, No.4, 275-281.

**Cost-Benefit Books:**

53. *Cost-Benefit Analysis and Dementia: New Interventions*. Edward Elgar, Cheltenham, UK. April, 2022.
54. *Advanced Introduction to Cost-Benefit Analysis*. Edward Elgar, Cheltenham, UK. October, 2017.
55. *Cost-Benefit Analysis and Health Care Evaluations*. (Second Edition) Edward Elgar, Cheltenham, UK, December 2014. [The First edition April 2003 (hardback). Paperback edition, March 2004.]
56. *Setting Priorities for HIV/AIDS: A Cost-Benefit Approach*. Edward Elgar, Cheltenham, UK, June 2010.
57. *Handbook on Research in Cost-Benefit Analysis* (Editor). Edward Elgar, Cheltenham, UK, 2009. [ 19 Chapters; 26 Contributors; 3 Chapters by the Editor.]
58. *Applied Cost-Benefit Analysis*. Second edition. Edward Elgar, Cheltenham, UK, December 2006. The first edition was: *Applied Cost-Benefit Analysis*. Edward Elgar, Cheltenham, UK, 1996 (hardback). Paperback edition, January 1997.
59. *Cost-Benefit Analysis for Developing Countries*. Edward Elgar, Cheltenham, UK, January 1998 (hardback). Paperback edition, May 2000. Previous edition published as: *Project Appraisal for Developing*

*Countries*. New York University Press, 1990. UK, Harvester-Wheatsheaf Books, 1990.

**Chapters in Books:**

60. "Treatment", Chapter 3.1: Perspectives Paper, pp 151–177. In Bjorn Lomberg (ed), *Rethink HIV: Smarter Ways to Invest in Ending HIV in Sub-Saharan Africa*. Cambridge University Press, Cambridge, UK, 2012.
61. "Overview of the Field and the Contributions in the Handbook." In Robert J. Brent, (ed), *Handbook on Research in Cost-Benefit Analysis*." Edward Elgar, Cheltenham, UK, 2009.
62. "Cost-Benefit Analysis , Environmental Projects and Distribution Weights." In Robert J. Brent, (ed), *Handbook on Research in Cost-Benefit Analysis*." Edward Elgar, Cheltenham, UK, 2009. [With Booi Themeli.]
63. "Cost-Benefit Analysis and the Evaluation of the Effects of Corruption on Public Projects." In Robert J. Brent, (ed), *Handbook on Research in Cost-Benefit Analysis*." Edward Elgar, Cheltenham, UK, 2009.
64. "The Numbers Effect, the Form of the Welfare Function, and the Social Discount Rate in Project Appraisal," in S. Bhagwan Dahiya (ed), *Theoretical Foundations of Development Planning, Vol 5, Project Evaluation*, Concepts Books, New Delhi, 1991.
65. "A Three Objective Social Welfare Function for Cost-Benefit Analysis," in S. Bhagwan Dahiya (ed), *Theoretical Foundations of Development Planning, Vol 5, Project Evaluation*, Concepts Books, New Delhi, 1991. [Reprint of article listed above.]
66. "On the Use of Distributional Weights in Cost-Benefit Analysis: A Survey of Schools," in S. Bhagwan Dahiya (ed), *Theoretical Foundations of Development Planning, Vol 5, Project Evaluation*, Concepts Books, New Delhi, 1991. [Reprint of article listed above.]

**Work in Progress:**

1. Cost-Benefit Analysis and Dementia [Book2]: Pharmaceutical Interventions.
2. "Using the Mini-Mental State Examination as a Surrogate for the Clinical Dementia Rating Scale when Evaluating Dementia Interventions."
3. "An Economic Evaluation of Antipsychotic Medications given to Persons with Dementia."
4. "A CBA of Non Steroidal Anti-Inflammatory drugs for Persons in Pain with Dementia."